State of New Jersey Common Pension Fund D Purchases New Position in Immunocore Holdings PLC Sponsored ADR $IMCR

State of New Jersey Common Pension Fund D bought a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,295 shares of the company’s stock, valued at approximately $292,000.

Several other hedge funds have also recently made changes to their positions in IMCR. Baker BROS. Advisors LP increased its stake in shares of Immunocore by 53.3% during the first quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company’s stock valued at $68,913,000 after buying an additional 807,338 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Immunocore by 5.2% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company’s stock valued at $209,228,000 after purchasing an additional 351,610 shares during the period. Frazier Life Sciences Management L.P. increased its position in Immunocore by 176.9% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 301,170 shares of the company’s stock valued at $8,936,000 after purchasing an additional 192,408 shares during the period. Fiera Capital Corp increased its position in Immunocore by 3.2% during the 1st quarter. Fiera Capital Corp now owns 805,150 shares of the company’s stock valued at $23,889,000 after purchasing an additional 25,186 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Immunocore during the first quarter valued at about $663,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Immunocore

In other news, insider David M. Berman sold 22,532 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $35.67, for a total transaction of $803,716.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.40% of the stock is currently owned by insiders.

Immunocore Trading Up 2.8%

NASDAQ IMCR opened at $33.09 on Monday. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $39.33. The stock has a market cap of $1.67 billion, a P/E ratio of -82.73 and a beta of 0.78. The stock’s fifty day moving average price is $33.87 and its 200-day moving average price is $33.10. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01.

Immunocore (NASDAQ:IMCR) last released its earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The firm had revenue of $130.65 million for the quarter, compared to analysts’ expectations of $122.96 million. During the same period in the prior year, the firm posted ($0.23) earnings per share. The company’s quarterly revenue was up 30.0% on a year-over-year basis. As a group, equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IMCR has been the topic of several research analyst reports. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 4th. Jefferies Financial Group initiated coverage on Immunocore in a report on Monday, August 25th. They set a “buy” rating and a $48.00 target price on the stock. Wells Fargo & Company initiated coverage on Immunocore in a research note on Friday. They issued an “overweight” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $60.89.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.